After three months of increasing trial disruptions, the number of disrupted trials began to fall between June and July. Most disruption was caused by the suspension of enrollment, followed by slow enrollment, and delayed initiation, says GlobalData, a data and analytics company.
Brooke Wilson, Associate Director, Trials Intelligence at GlobalData, comments, “Although the total number of disrupted trials is decreasing overall, of trials that listed disruption as suspension of enrollment, slow enrollment or delayed initiation as their reason for disruption, only those affected by suspended enrollment have reduced (by 17.3%) compared to last month. Meanwhile, trials with delayed initiation have risen by 10% and trials that have been impacted by slow enrollment have gone up by 13.9%. This suggests that trials that had already initiated enrollment before the pandemic, with chosen sites and investigators, but then suspended due to COVID-19, are having more success picking up where they left off as long as enrollment wasn't impacted.”
Within the category of trials affected by slow enrollment, one-tenth are specifically due to the availability of sites and investigators. The reasons for this include that trial site hospitals are overwhelmed with COVID-19 patients, repurposed investigators, deprioritized non-COVID-19 trials, and high-risk subjects unwilling to enroll due to a greater chance of contracting COVID-19
Wilson continues: “Importantly, the total number of disrupted trials is falling and the number of clinical trials that have resumed has almost doubled since last month. This implies that sponsors and contract service providers have begun to adjust clinical trial design strategies and are adapting to the new post-COVID-19 environment.”
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.